Terry D Heiman-Patterson
Overview
Explore the profile of Terry D Heiman-Patterson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
827
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hollin I, Giler G, Heiman-Patterson T
Neurology
. 2025 Jan;
104(4):e210015.
PMID: 39883905
Background And Objectives: Clinical care for people living with amyotrophic lateral sclerosis (PLWALS) is directed at slowing disease progression and symptom management. The American Academy of Neurology recommends a multidisciplinary...
2.
Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD
Benatar M, Heiman-Patterson T, Cooper-Knock J, Brickman D, Casaletto K, Goutman S, et al.
J Neurol Neurosurg Psychiatry
. 2024 Nov;
PMID: 39572211
There is a growing understanding of the presymptomatic stages of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and nascent efforts aiming to prevent these devastating neurodegenerative diseases have emerged....
3.
Gwathmey K, Heiman-Patterson T
Continuum (Minneap Minn)
. 2023 Oct;
29(5):1585-1594.
PMID: 37851044
Multidisciplinary care is comprehensive, coordinated clinical care across medical disciplines and allied health professions. Neuromuscular disorders, such as amyotrophic lateral sclerosis and muscular dystrophies, are often associated with disabling weakness...
4.
Alexander G, Heiman-Patterson T, Bearoff F, Sher R, Hennessy L, Terek S, et al.
PLoS One
. 2022 Sep;
17(9):e0274615.
PMID: 36107978
Amyotrophic lateral sclerosis (ALS) is the most common degenerative motor neuron disorder. Although most cases of ALS are sporadic, 5-10% of cases are familial, with mutations associated with over 40...
5.
Paganoni S, Hendrix S, Dickson S, Knowlton N, Berry J, Elliott M, et al.
J Neurol Neurosurg Psychiatry
. 2022 May;
PMID: 35577511
Background: Coformulated sodium phenylbutyrate/taurursodiol (PB/TURSO) was shown to prolong survival and slow functional decline in amyotrophic lateral sclerosis (ALS). Objective: Determine whether PB/TURSO prolonged tracheostomy/ventilation-free survival and/or reduced first hospitalisation...
6.
Johnson J, Miller D, Li R, Kumaran R, Alahmady N, Cookson M, et al.
JAMA Neurol
. 2021 Aug;
78(10):1236-1248.
PMID: 34459874
Importance: Juvenile amyotrophic lateral sclerosis (ALS) is a rare form of ALS characterized by age of symptom onset less than 25 years and a variable presentation. Objective: To identify the...
7.
Heiman-Patterson T, Khazaal O, Yu D, Sherman M, Kasarskis E, Jackson C
Amyotroph Lateral Scler Frontotemporal Degener
. 2021 Aug;
22(sup1):54-61.
PMID: 34348540
There has been no comprehensive longitudinal study of pulmonary functions (PFTS) in ALS determining which measure is most sensitive to declines in respiratory muscle strength. To determine the longitudinal decline...
8.
Heiman-Patterson T, Sherman M, Yu D, Jackson C, George A, Kasarskis E
Amyotroph Lateral Scler Frontotemporal Degener
. 2021 Aug;
22(sup1):48-53.
PMID: 34348538
: To develop an ALS respiratory symptom scale (ARES) and evaluate how ARES compares to Medical Research Council Modified Dyspnea Scale (MRC), Borg dyspnea scale, and respiratory subscores from ALSFRS-R...
9.
Paganoni S, Hendrix S, Dickson S, Knowlton N, Macklin E, Berry J, et al.
Muscle Nerve
. 2020 Oct;
63(1):31-39.
PMID: 33063909
An orally administered, fixed-dose coformulation of sodium phenylbutyrate-taurursodiol (PB-TURSO) significantly slowed functional decline in a randomized, placebo-controlled, phase 2 trial in ALS (CENTAUR). Herein we report results of a long-term...
10.
Andrews J, Jackson C, Heiman-Patterson T, Bettica P, Brooks B, Pioro E
Amyotroph Lateral Scler Frontotemporal Degener
. 2020 Jun;
21(7-8):509-518.
PMID: 32573277
To compare the effect of riluzole on median survival in population studies of patients with amyotrophic lateral sclerosis (ALS) with that observed in clinical trials. : Two independent PubMed searches...